newsfilter
← Latest News
GlobeNewswire·

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase 1 trial ongoing,